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BACKGROUND: L-DOPA decarboxylase (DDC) is an enzyme that catalyses, mainly, the decarboxylation of L-DOPA to dopamine and
was found to be involved in many malignancies. The aim of this study was to investigate the mRNA expression levels of the DDC gene
and to evaluate its clinical utility in tissues with colorectal adenocarcinoma.
METHODS: Total RNA was isolated from colorectal adenocarcinoma tissues of 95 patients. After having tested RNA quality, we
prepared cDNA by reverse transcription. Highly sensitive quantitative real-time PCR method for DDC mRNA quantification was
developed using the SYBR Green chemistry. GAPDH served as a housekeeping gene. Relative quantification analysis was performed
using the comparative CT method (2
 DDCT).
RESULTS: DDC mRNA expression varied remarkably among colorectal tumours examined in this study. High DDC mRNA expression
levels were found in well-differentiated and Dukes’ stage A and B tumours. Kaplan–Meier survival curves showed that patients with
DDC-positive tumours have significantly longer disease-free survival (P¼0.009) and overall survival (P¼0.027). In Cox regression
analysis of the entire cohort of patients, negative DDC proved to be a significant predictor of reduced disease-free (P¼0.021) and
overall survival (P¼0.047).
CONCLUSIONS: The results of the study suggest that DDC mRNA expression may be regarded as a novel potential tissue biomarker in
colorectal adenocarcinoma.
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Colorectal carcinoma (CRC) is the third most common malignant
tumour and the fourth most common cause of cancer death in the
world (Parkin et al, 2001a; Jemal et al, 2009). The prognosis of
patients with CRC largely depends on the degree of penetration of
the tumour through the bowel wall, the nodal status, and the
presence or absence of distal metastases (Steinberg et al, 1986).
These three characteristics are the key features of all clinical
staging systems developed for this disease (Compton and Greene,
2004).
In spite of the fact that clinicopathological staging separates
patients with CRC into groups with distinct outcomes, it provides
little information about response to treatment in individual
patients (Walther et al, 2009). In an attempt to refine prognostica-
tion and predict the benefit derived from systemic treatment,
several protein and genetic markers have been evaluated in
patients with CRC, including allelic loss of chromosome 18q (Jen
et al, 1994; Martinez-Lopez et al, 1998; Ogunbiyi et al, 1998; Popat
and Houlston, 2005), absence of the deleted in colorectal
carcinoma (DCC) protein (Shibata et al, 1996; Reymond et al,
1998; Popat and Houlston, 2005), decreased SMAD4 mRNA
expression (Boulay et al, 2002; Alazzouzi et al, 2005), expression
and/or abnormalities of cytoplasmic oncoprotein p53 (TP53) (Sun
et al, 1992; Munro et al, 2005; Russo et al, 2005), protein levels
and/or gene haplotype of thymidylate synthetase (TYMS) (Popat
et al, 2004; Suh et al, 2005; Tsourouflis et al, 2008), microsatellite
instability (MSI) (Gryfe et al, 2000; Popat et al, 2005), and
chromosomal instability (CIN) (Walther et al, 2008). Nevertheless,
none of these biomarkers has been prospectively validated and
established so far in clinical practice. Hence, the identification of
new, reliable prognostic and predictive biomarkers that will
contribute utmost to clinical decision-making, remains an
important research topic (Locker et al, 2006; Walther et al, 2009).
L-DOPA decarboxylase (DDC) is a pyridoxal 5-phosphate
(PLP)-dependent enzyme that catalyses the decarboxylation of
3,4-dihydroxy-L-phenylalanine (L-DOPA) to dopamine (DA) and
5-hydroxy-L-tryptophan (S-HTP) to serotonin (5-HT) (Christenson
et al, 1972). DDC is expressed in the central nervous system as well
as in peripheral organs, such as the liver, kidney, pancreas and
placenta (Lindstrom and Sehlin, 1983; Maneckjee and Baylin, 1983;
Ichinose et al, 1989; Mappouras et al, 1990; Siaterli et al, 2003).
Moreover, enzymatically active DDC was recently found in human
leukocytes as well as in the histiocytic lymphoma cell line U-937,
thus suggesting a cross-talk between the nervous and the immune
systems and raising new questions about the regulatory role of
DDC in immune responses (Kokkinou et al, 2009a,b). Recently,
two endogenous inhibitors of the enzymatic activity of DDC have
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sbeen identified and purified, one from human serum and another
from the membrane fraction of human placental tissue, yet their
biological significance remains unexplored (Vassiliou et al, 2005,
2009).
The structure of the human DDC gene has been fully
determined. The single-copy gene encoding DDC maps to
chromosome 7p12.2, close to the epidermal growth factor receptor
(EGFR) gene, and is composed of 15 exons spanning a genomic
region of more than 85kb (Ichinose et al, 1989; Sumi-Ichinose
et al, 1992). Furthermore, two other DDC mRNA transcripts
encoding distinct DDC protein isoforms as well as alternative
splicing in 50-untranslated region have been identified and
characterised (Krieger et al, 1991; Ichinose et al, 1992; O’Malley
et al, 1995; Vassilacopoulou et al, 2004).
It is worth mentioning that DDC is regarded as a general
biomarker for neuroendocrine tumours (Gazdar et al, 1988; Gilbert
et al, 1995; Ippolito et al, 2005). High DDC mRNA expression has
been noticed in small-cell lung carcinoma (SCLC), neuroblastoma,
and pheochromocytoma (Jensen et al, 1990; Gilbert et al, 1999;
Uccella et al, 2006). Moreover, it has been suggested that DDC
mRNA levels could be a potential biomarker for the detection of
minimal residual disease in patients with neuroblastoma and for
the discrimination of neuroblastoma from other small round-cell
tumours of childhood (Gilbert et al, 1999; Bozzi et al, 2004).
Recent studies revealed that DDC is also implicated in prostate
cancer neuroendocrine differentiation, accounting for abnormal
prostate cell proliferation and differentiation (Wafa et al, 2007), as
it is an androgen receptor (AR) coregulator protein acting at the
cytoplasmic level to enhance AR activity and to differentially
modulate AR-regulated genes (Wafa et al, 2003; Margiotti et al,
2007). Not surprisingly, DDC gene expression at the mRNA level
has been proposed as a novel tissue biomarker in prostate cancer
(Avgeris et al, 2008). DDC is also overexpressed in peritoneal
dissemination of gastric carcinoma, and its quantification has been
shown to be reliable and effective for the selection of patients for
adjuvant intraperitoneal chemotherapy, aiming at preventing
peritoneal recurrence (Sakakura et al, 2004). Still, the role of
DDC in CRC remains unclear.
The above data encouraged us to analyse the DDC mRNA
expression in colorectal adenocarcinoma specimens, developing
an ultra-sensitive and highly accurate quantitative real-time PCR
methodology using the SYBR Green chemistry, and to examine its
potential prognostic significance and clinical application as a novel
molecular tissue biomarker for colorectal adenocarcinoma.
MATERIALS AND METHODS
Tissue samples and RNA isolation
Included in this study were tumour specimens from 95 patients
having undergone surgical treatment for primary colorectal
adenocarcinoma between 2000 and 2003. The selection criteria
for the specimens included the availability of sufficient tissue mass
for RNA extraction and assay. Tumour tissues had been frozen in
liquid nitrogen immediately after their surgical resection.
Tissue specimens were pulverised and then dissolved in TRI
Reagent (Ambion (Europe) Ltd., Huntingdon, UK). Following the
manufacturer’s instructions, we extracted and diluted total RNA in
an RNA Storage Solution (Ambion Ltd), and stored it at  801C
until use.
Patient age ranged from 35 to 88 years with a mean±s.e. of
67.3±1.01. Other patients’ characteristics and stage of tumours are
shown in Tables 1–3. Follow-up information was available for
72 patients and included survival status (alive or deceased) and
disease status (disease-free or recurrence/metastasis) along with
the dates of the events and cause of death.
The study was performed with respect to the ethical standards of
the 1975 Declaration of Helsinki Principles, as revised in 1996, and
Table 1 Distribution of numerical variables of the study in 95 colorectal
adenocarcinoma patients
Percentiles
25 50 75
Variable Mean±s.e.
a Range Median
DDC in tumours (c/Kc
b) 9.02±1.51 0.04–91.95 0.17 3.09 12.82
Patient age (years) 67.3±1.01 35–88 62.0 68.0 75.0
DFS (months) 36.6±2.63 0.5–79.0 16.7 39.5 52.2
OS (months) 38.1±2.63 0.5–79.0 17.7 42.5 54.2
Abbreviations: DDC¼ L-DOPA decarboxylase; DFS¼disease-free survival;
OS¼overall survival.
aStandard error of the mean.
bDDC mRNA copies per 1000
GAPDH mRNA copies.
Table 2 Relationships between DDC status
a and other clinicopatho-
logical variables
Number of patients (%)
Variable Total DDC negative
a DDC positive
a P-value
Nodal status
Positive 49 35 (71.4) 14 (28.6) 0.63
b
Negative 41 32 (78.0) 9 (22.0)
X5
Stage
c
A/B 47 33 (70.2) 14 (29.8) 0.13
b
C/D 41 35 (85.4) 6 (14.6)
X7
Histologic grade
I 6 2 (33.3) 4 (66.7) 0.011
d
II 70 51 (72.9) 19 (27.1)
III 11 11 (100) 0 (0.00)
X8
Abbreviations: DDC¼ L-DOPA decarboxylase; x¼status unknown.
aCut-off point:
12.82c/Kc, equal to the 75th percentile.
bCalculated by Fisher’s exact test.
cDukes’
staging system.
dCalculated by w
2-test.
Table 3 DDC expression and survival of patients with colorectal
adenocarcinoma
Disease-free survival Overall survival
Variable HR
a 95% CI
b P-value HR
a 95% CI
b P-value
Univariate analysis
DDC
Negative 1.00 1.00
Positive 0.18 0.043–0.77 0.021 0.23 0.053–0.97 0.047
As continuous variable 0.96 0.93–1.00 0.089 0.95 0.90–1.00 0.089
Nodes positive 1.80 0.83–3.89 0.13 2.69 1.11–6.51 0.027
Stage (ordinal) 2.31 1.42–3.73 0.001 2.53 1.48–4.34 0.001
Histologic grade (ordinal) 3.07 1.33–7.05 0.008 3.92 1.57–9.74 0.003
Multivariate analysis
c
DDC
Negative 1.00 1.00
Positive 0.37 0.08–1.67 0.19 0.56 0.12–2.67 0.46
Nodes positive 0.76 0.29–2.00 0.58 1.14 0.36–3.58 0.82
Stage (ordinal) 2.31 1.30–4.10 0.004 2.32 1.14–4.74 0.021
Histologic grade (ordinal) 2.13 0.86–5.30 0.103 2.70 0.98–7.41 0.054
Abbreviations: CI¼confidence interval; DDC¼ L-DOPA decarboxylase; HR¼hazard
ratio.
aHR estimated from Cox proportional hazard regression model.
bCI of the
estimated HR.
cMultivariate models were adjusted for patients’ nodal status, Dukes’
stage, and histologic tumour grade.
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shas been approved by the ethics committee of the University
General Hospital ‘Attikon’.
cDNA synthesis
First-strand cDNA was produced from total RNA by using an RNA
PCR Kit Version 3.0 (TaKaRa Bio Inc., Tokyo, Japan), according to
the manufacturer’s instructions. The reaction mixture contained
2mg of total RNA diluted in 11ml of diethylpyrocarbonate (DEPC)-
treated water, 2.5pmol Oligo dT-Adaptor primer, 2ml RT Buffer
(10 , 100mM Tris-HCl (pH¼8.3), 500mM KCl), 4ml5m M MgCl2,
2ml1 0 m M dNTP mix, 20U RNase inhibitor (Rnase Inhibitor;
40Uml
 1; TaKaRa Bio Inc.) and 1.25U reverse transcriptase (AMV
Reverse Transcriptase XL; 5Uml
 1; TaKaRa Bio Inc.). The final
reaction volume was 20ml. The reaction mixture was incubated at
301C for 10min, 601C for 30min, and the reaction was terminated
by heating the mixture at 991C for 5min and cooling it at 51C for
5min.
Real-time quantitative PCR
Quantitative real-time PCR was performed using the SYBR Green
chemistry in a 7500 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA) (Figure 1A). On the basis of the information
of the DDC and GAPDH cDNA sequences, two pairs of gene-
specific primers were designed. The reaction mixture contained
50ng of cDNA diluted in 2.5ml of DEPC-treated water, 5ml Power
SYBR Green PCR Master Mix (2 ) (Applied Biosystems), and 2ml
of gene-specific primers (final concentration, 50nM each), in a
final reaction volume of 10ml. The DDC real-time PCR primers
were 50-GAACAGACTTAACGGGAGCCTTT-30 and 50-AATGCCGG
TAGTCAGTGATAAGC-30, producing a 90-bp PCR amplicon, and
the GAPDH real-time PCR primers were 50-ATGGGGAAGGTG
AAGGTCG-30 and 50-GGGTCATTGATGGCAACAATATC-30, re-
sulting in a 107-bp PCR amplicon. The cycling conditions were
as follow: a denaturation step at 951C for 10min, followed by
40 cycles of 951C for 15s, 601C for 60s, and a final step for the
generation of a dissociation curve to distinguish between the main
PCR product and primer-dimers (Figure 1B).
Calculations were made with the use of the comparative CT
(2
 DDCT) method. GAPDH was used as an internal control gene to
normalise the PCRs for the amount of RNA added to the reverse
transcription reactions, whereas the breast adenocarcinoma
epithelial cell line MCF7 was used as a calibrator for making PCRs
from distinct runs comparable (Livak and Schmittgen, 2001).
DDCT represents the difference between the mean DCT value of a
colon sample and the mean DCT of the calibrator, both calculated
after the same PCR run, whereas DCT is the difference between the
threshold cycle (CT) of the target gene (DDC) and the CT of the
endogenous reference gene (GAPDH) of the same sample.
Normalised results were expressed as the ratio of DDC mRNA
copies to GAPDH mRNA copies calculated for each colon tissue
sample in relation to the same ratio calculated for MCF7 cells. The
normalised (2
 DDCT) amounts of tissue sample DDC mRNA levels
were then multiplied with the average ratio of DDC mRNA copies
to GAPDH mRNA copies of MCF7 cells (2
 13.384), calculated from
the intercept of the regression line shown in Figure 1C, thus
resulting in comparable results that do not depend on the DDC
mRNA expression levels of MCF7 cells. Finally, these results were
multiplied by 1000, thus yielding c/Kc (DDC mRNA copies per
1000 GAPDH mRNA copies). Each real-time PCR reaction was
performed in triplicate to evaluate the reproducibility of data.
Statistical analysis
The X-tile algorithm was used to generate an optimal cut-off point
for DDC (Camp et al, 2004), as there are no established cut-off
points concerning its expression in colorectal adenocarcinoma.
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Figure 1 Real-time PCR quantification of DDC gene expression in colon
tissues. (A) Amplification plot of DDC and GAPDH cDNAs, showing DRn
plotted vs cycle number. DDC mRNA expression was detected by real-time
quantitative PCR, using the SYBR Green chemistry, while GAPDH served as
a reference gene. Calculations were made with the use of the comparative
CT (2 DDCT) method. (B) Dissociation curves of the DDC amplicon,
showing the specificity of primers used for the real-time PCR amplification
and quantification of DDC. Neither primer-dimers nor other non-specific
products were observed after melting of the PCR products. (C) Validation
of the comparative CT (2 DDCT) method. The efficiency of the amplification
of the target gene (DDC) and internal control (GAPDH) was examined by
means of real-time PCR and SYBR Green detection. With the use of
reverse transcriptase, cDNA was synthesised from 2mg total RNA isolated
from human MCF7 cells. Serial dilutions of cDNA over a 100-fold range
were amplified by real-time PCR using gene-specific primers. The
most concentrated sample contained cDNA derived from 100ng of total
RNA. The DCT (CT,DDC–CT,GAPDH) was calculated for each cDNA dilution
and plotted vs it. All data were fit using least-square linear regression
analysis. The absolute value of the slope of the resulting plot is almost equal
to zero, which indicates that the amplification efficiencies for both genes are
similar.
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sHaving corrected for the use of minimum P-value statistics, the
X-tile software yielded an optimal cut-off of 12.82c/Kc, equal to
the 75th percentile, with a calculated Monte Carlo P-value o0.05.
According to this cut-off, DDC mRNA expression was classified as
positive or negative, and associations between DDC status and
other qualitative clinicopathological parameters were analysed
using the w
2-test or the Fisher’s exact test, where appropriate.
Cox proportional hazard regression model was developed to
assess the association between the prognostic markers and the
relative risks for relapse and death of patients (Cox, 1972). Cox
analysis was conducted at both univariate and multivariate levels.
Only patients for whom the status of all variables was known were
included in the multivariate regression models, which incorpo-
rated DDC mRNA expression and all other variables for which the
patients were characterised. The multivariate models were adjusted
for nodal status, histologic tumour grade, and Dukes’ stage (Dukes,
1932; Hamilton and Aaltonen, 2000).
Survival analyses were also performed by constructing Kaplan–
Meier disease-free survival (DFS) and overall survival (OS) curves
(Kaplan and Meier, 1958). The differences between the curves were
evaluated by the log-rank test.
RESULTS
Validation of the comparative CT (2
 DDCT) method for DDC
mRNA quantification
For the DDCT calculation to be valid, the amplification efficiencies
of the target and reference genes must be approximately equal
(Livak and Schmittgen, 2001). For this purpose, the CT values for
DDC and GAPDH, corresponding to the number of cycles at which
the fluorescence emission monitored in real time reached a
threshold of 10 times the standard deviation of the mean baseline
emission from cycles 3 to 15 (Figure 1A) (Giulietti et al, 2001),
were measured in serial dilutions of a control cDNA over a 100-
fold range, and the DCT (namely the difference CT,DDC–CT,GAPDH)
was plotted vs the log cDNA dilution. The absolute value of the
slope of the resulting plot is close to zero, which implies similar
amplification efficiencies of both amplicons (Figure 1C).
DDC expression status in colorectal adenocarcinoma
tissues and its association with patients’
clinicopathological variables
mRNA expression of DDC in colorectal adenocarcinoma tissues
varied from 0.04 to 91.95c/Kc (DDC mRNA copies per 1000
GAPDH mRNA copies) with a mean±s.e. of 9.02±1.51 (Table 1).
Table 2 shows the association of DDC mRNA expression status of
the tumour with various clinicopathological variables. DDC values
were classified into two categories (positive or negative), as
described in the Materials and Methods section. Out of 95 colon
adenocarcinomas examined, 24 (25.3%) were classified as positive
for DDC expression and 71 (74.7%) as negative. DDC positivity was
found more frequently in well-differentiated tumours, whereas
high-grade colorectal tumours were found to be DDC-negative
(P¼0.011). Significant associations between DDC status and
patient age, nodal status, or Dukes’ stage were not observed.
DDC expression status and colorectal adenocarcinoma
survival
Complete follow-up information was available for 72 patients,
among whom 27 (38%) had relapsed and 22 (31%) had died.
In Cox univariate analysis, histologic tumour grade, and disease
Dukes’ stage were significant predictors of DFS and OS, as
expected. In addition to these established prognostic factors, DDC
mRNA expression was found to be an important predictor of DFS
and OS (P¼0.021 and P¼0.047, respectively). DDC-positive
patients were found to have a significant lower risk to relapse
(HR¼0.18) or die (HR¼0.23) (Table 3). The Kaplan–Meier
survival curves also show that patients with DDC-positive tumours
have remarkably longer DFS (P¼0.009) and OS (P¼0.027),
compared to those with DDC-negative malignancies (Figure 2). In
multivariate analysis, when all parameters were included in the
Cox regression model, only Dukes’ stage retained its prognostic
significance for DFS and OS of patients with colorectal adeno-
carcinoma (P¼0.004 and P¼0.021, respectively) (Table 3).
DISCUSSION
Cancer of the colon and rectum is an important public health issue,
constituting a major cause of worldwide morbidity and mortality
(Pisani et al, 2002; Jemal et al, 2009). In Europe, CRC is the second
most common malignancy among women after breast cancer and
the third most frequent in men after prostate and lung cancer.
Moreover, CRC is the second most common cause of cancer death
for both sexes, accounting for 12% of all tumour-related deaths
(Parkin et al, 2001b; Ferlay et al, 2010). Early diagnosis of CRC
and early detection of recurrence after surgery are critical for
effective treatment and/or positive clinical outcome. Endoscopic
examination of the colon remains the most reliable screening
method for this type of malignancy (Newcomb et al, 1992;
Lieberman et al, 2000).
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Figure 2 Kaplan–Meier survival curves. Kaplan–Meier curves for disease-free survival (DFS) (A) and overall survival (OS) (B) of patients with
DDC-positive and DDC-negative colorectal adenocarcinoma. DDC expression was found to have a favourable prognostic value for colorectal
adenocarcinoma, as patients with DDC-positive colorectal adenocarcinoma have significantly longer DFS (P¼0.009) and OS (P¼0.027), in comparison with
those whose tumours are DDC-negative.
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sAll existing classification systems for CRC distinguish between
patients with early-stage CRC and those with very advanced-stage
disease; nonetheless, they are less efficient in predicting the
prognosis of patients with intermediate levels of tumour burden
(McLeod and Murray, 1999). On the basis of studies published
over the last few years, the American Society of Clinical Oncology
Tumour Marker Panel and the European Group on Tumour
Markers have recently suggested that preoperative carcinoem-
bryonic antigen (CEA) levels may be used as an independent
prognostic factor, assisting in staging and surgical treatment
planning. It should also be noted that CEA is the marker of choice
for monitoring the response of metastatic disease to systemic
therapy (Duffy et al, 2003; Locker et al, 2006). However, neither
CEA nor any other biomarkers that have been proposed in the
past, such as CA19-9, have enough sensitivity for colon cancer
detection (van der Schouw et al, 1992; Pokorny et al, 2000; Locker
et al, 2006).
L-DOPA decarboxylase is a PLP-dependent enzyme participating
in the catecholamine biosynthesis pathway, responsible principally
for the synthesis of the key neurotransmitters DA and 5-HT
(Christenson et al, 1972). Biogenic amines are generally considered
to participate in various processes, such as angiogenesis, cell
proliferation, differentiation and apoptosis (Berry et al, 1996;
Medina et al, 1999; Lang et al, 2005), which implies a potentially
significant role of DDC in cancer pathobiology and progression.
Interestingly enough, it has recently been shown that catechola-
mines, including DA itself, inhibit erythrocyte apoptosis by
preventing scramblase activation and subsequent phosphatidyl-
serine exposure on the cell membrane (Lang et al, 2005), which in
turn triggers clearance of apoptotic cells by macrophages.
DDC mRNA expression is used for the differential diagnosis of
neuroblastoma from other pediatric small round-cell malignancies
(Gilbert et al, 1999; Bozzi et al, 2004). Quantification of DDC
mRNA expression using real-time RT-PCR has been proposed as a
method useful for the prediction of peritoneal recurrence in
patients with gastric carcinoma (Sakakura et al, 2004). In addition,
DDC protein expression is a biomarker of neuroendocrine
differentiation in SCLC cells and prostate carcinoma (Gilbert
et al, 2000; Wafa et al, 2007). DDC mRNA levels were also found to
be particularly elevated in cancerous prostate tissue, in compar-
ison with benign prostate hyperplasia. High-expression levels of
DDC were found to be associated with more aggressive prostate
tumours (Avgeris et al, 2008).
Several peripheral cancers are characterised by an extremely
high DDC activity, associated with the tumour. This is especially
apparent with lung cancers of small-cell origin, although variants
showing no protein expression have been observed as well (Berry
et al, 1996). Remarkable increase in DDC activity, in comparison
with normal tissue levels, is also seen in primary intestinal cancer
and its related metastases in the spleen and liver (Gilbert et al,
1995). The significance of this increase in DDC activity and
resultant monoamine synthesis by the cancer cells is still unknown
(Berry et al, 1996), yet it is closely related to the implication of
DDC in cancer.
In this study, we investigated the expression of the DDC gene
in colorectal adenocarcinoma and its prognostic significance.
Our study revealed a statistically significant, negative association
between DDC mRNA expression levels and the histologic tumour
grade (P¼0.011). Colorectal tumours of low histologic grade (I)
were more frequently DDC-positive, in contrast with malignancies
of high grade (II/III). These data seem to indicate that higher
DDC expression is associated with well-differentiated intestinal
tumours.
In accordance with the above-mentioned results, the Kaplan–
Meier analysis showed significantly higher DFS and OS time for
patients having positive DDC mRNA expression (P¼0.009 and
P¼0.027, respectively). Cox univariate regression analysis showed
that DDC-positive patients had a significantly lower risk of relapse
( B5 times) and a higher probability of survival (B4 times). In the
Cox multivariate regression model, the levels of DDC mRNA were
adjusted for patients’ nodal status, Dukes’ stage and histologic
tumour grade. When all these non-molecular parameters were
included in the multivariate analysis model, DDC mRNA expres-
sion did not show statistically significant independence as a
prognostic factor for DFS or OS of patients with colorectal
adenocarcinoma.
In conclusion, this study revealed that higher mRNA expression
levels of DDC are related with less advanced and/or aggressive
tumours. Our results imply that DDC mRNA overexpression is
linked to favorable prognosis in patients with colorectal adeno-
carcinoma and may constitute a useful tissue biomarker. Involve-
ment of DDC in apoptosis of colon cancer cells and/or response
of DDC-positive tumours to chemotherapy are two potential
explanations, but further investigation is required to clarify the
role of DDC in CRC.
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